Info

Biotecnol is a biotechnology company focused on the development of biopharmaceutical products and has a special focus on the development of antibody-based therapeutics to treat life-threatening diseases such as cancer. Biotecnol applies its antibody technologies, product development and manufacturing experience to generate, support and potentially license out human antibody products. Biotecnol SA has a presence in the USA and carries its product development activities via its fully owned subsidiary Biotecnol Inc. Through its facility in Portugal, Biotecnol SA, leverages its business income by establishing in-house partner-led or collaborative programmes, which provide Biotecnol a strong client-based activity and an established track record. Biotecnol uses its proprietary expression technology, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering GMP/GLP compliant processes for biomanufacturing. Biotecnol has various types of proprietary antibody formats in development against various cancer targets. Biotecnol is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs.